Key Takeaways
- Argenx (ARGX) declined 1.00% even as third-quarter VYVGART revenue hit $1.7 billion.
- Net income rose to $506 million, yet investor sentiment remained cautious on the biotech stock.
- Year-over-year product sales surged 54% as the company broadened its autoimmune treatment portfolio.
- Operating expenses climbed to $1.27 billion during the quarter, driven by R&D and acquisition costs.
- Empasiprubart Phase 3 data expected in December could represent a pivotal catalyst for the stock.
Shares of Argenx SE (ARGX) retreated despite the biotech company delivering robust third-quarter financial results and expanding profit margins. The stock dropped 1.00%, closing at $881.15 after shedding $8.90 in value. Trading remained choppy throughout the session, with shares bouncing from early weakness before encountering resistance near the $890 level.
Blockbuster VYVGART Performance Powers Revenue Growth
The Netherlands-based biotech company posted product revenue of $1.72 billion for the third quarter, marking a 54% increase compared to the prior-year period. Sequential growth came in at 13% as patient demand continued to expand across key therapeutic indications. Argenx markets VYVGART as a treatment option for autoimmune disorders such as generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Overall operating revenue totaled $1.75 billion during the quarter, compared to $1.15 billion in the same three-month span last year. Operating profit for the period came to $486 million, up from $346 million twelve months earlier. The company reported net income of $506 million versus $344 million year-over-year, translating to basic earnings per share of $8.07.
On a nine-month basis, VYVGART generated $4.53 billion in sales compared to $2.87 billion during the first three quarters of the previous year. Operating profit for the nine-month period doubled to $1.37 billion, underscoring accelerating commercial momentum. Still, the biotech firm significantly elevated its investment in pipeline development, commercial infrastructure, and strategic transactions.
Spending Surge Reflects Expansion Ambitions
Operating expenses jumped to $1.27 billion in the quarter, up sharply from $805 million in the year-ago period. Research and development outlays climbed to $503 million as the company pushed forward with multiple clinical trials spanning various disease states. Selling, general, and administrative costs reached $598 million, well above the $336 million recorded in last year’s third quarter.
The administrative expense line included roughly $150 million tied to the Forte Biosciences acquisition, which Argenx completed for approximately $2.1 billion net of acquired cash. Cash and current financial assets stood at $3.7 billion at the end of September, down from $4.4 billion at year-end. The reduction reflects acquisition funding and operational spending over the first nine months.
Management now projects combined research, development, and administrative costs will approach $4 billion for the full year 2026. This guidance incorporates Forte-related expenses as well as ongoing investments to support global VYVGART commercialization. The revised spending outlook reflects the company’s commitment to scaling both its marketed products and investigational assets.
Regulatory Filings and Clinical Readouts Loom
Argenx filed a supplemental application with the FDA seeking approval for VYVGART in ocular myasthenia gravis. The agency also granted priority review status for VYVGART in pediatric generalized myasthenia gravis, with an action date set for February 2027. The company anticipates launching a VYVGART Hytrulo autoinjector in the latter half of next year to improve patient convenience.
Phase 3 ALKIVIA trial results came back positive, paving the way for regulatory submissions in immune-mediated muscle disease. Argenx expects to file an application for immune-mediated necrotizing myopathy before the end of this year. In addition, topline data from the empasiprubart Phase 3 trial in multifocal motor neuropathy is anticipated in December, representing a near-term inflection point.
The biotech is also preparing to advance FB102 into Phase 3 development for celiac disease after encouraging earlier-stage data. Under its Vision 2030 strategic framework, argenx aims to treat 50,000 patients, secure 10 approved indications, and advance five candidates into registrational studies. Even with strong operational performance and pipeline momentum, shares faced persistent downward pressure during the session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
